Subtopic Deep Dive
Pharmacogenomics of Thiopurine Therapy
Research Guide
What is Pharmacogenomics of Thiopurine Therapy?
Pharmacogenomics of thiopurine therapy studies genetic variants in TPMT and NUDT15 that influence thiopurine metabolism, toxicity, and efficacy in acute lymphoblastic leukemia treatment.
Thiopurines like mercaptopurine are mainstays of ALL maintenance therapy, but polymorphisms cause severe myelosuppression in 1/178 TPMT-deficient patients (Relling et al., 2011, 565 citations). NUDT15 variants emerged as key determinants of intolerance, especially in non-Europeans (Yang et al., 2015, 427 citations). Over 20 papers detail dosing guidelines and clinical implementation.
Why It Matters
TPMT genotyping reduces thiopurine-induced toxicities, enabling safe dosing and improving ALL survival rates (Relling et al., 2011). NUDT15 testing personalizes therapy for Asian and Hispanic patients, cutting severe adverse events by 80% (Yang et al., 2015). Cost-effectiveness analyses confirm genotyping saves €1,500 per patient in Europe by averting hospitalizations (van den Akker-van Marle et al., 2006). NCCN guidelines now recommend pre-treatment screening (Brown et al., 2020).
Key Research Challenges
Ethnic Variability in Alleles
TPMT variants predominate in Europeans, while NUDT15 variants affect 15-20% of Asians, complicating universal dosing (Yang et al., 2015). GWAS identified NUDT15 codon 139 as predictive in Japanese IBD cohorts (Kakuta et al., 2018). Multi-ethnic algorithms remain underdeveloped.
Prospective Clinical Validation
Retrospective studies dominate; randomized trials for TPMT/NUDT15-guided dosing in ALL are scarce (Moriyama et al., 2015). NCCN endorses but lacks level 1 evidence (Brown et al., 2020). Real-world implementation varies by healthcare system.
Metabolite Monitoring Integration
TPMT activity assays correlate poorly with 6-thioguanine levels during therapy (Lowry et al., 2001). Combining genotyping with TGN measurements improves outcomes but lacks standardized protocols (Toksvang et al., 2022).
Essential Papers
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
Mary V. Relling, E E Gardner, William J. Sandborn et al. · 2011 · Clinical Pharmacology & Therapeutics · 565 citations
Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine dose...
Inherited <i>NUDT15</i> Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia
Jun J. Yang, Wendy Landier, Wenjian Yang et al. · 2015 · Journal of Clinical Oncology · 427 citations
Purpose Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL). We performed a genome-wide association study (GWAS) to identify comprehensively the genetic b...
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease
Philip W. Lowry, C L Franklin, A L Weaver et al. · 2001 · Gut · 230 citations
BACKGROUND Measurement of 6-thioguanine nucleotide concentrations may be useful for optimising treatment with azathioprine and 6-mercaptopurine. METHODS We conducted a study of 170 patients with in...
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Patrick A. Brown, Hiroto Inaba, Colleen Annesley et al. · 2020 · Journal of the National Comprehensive Cancer Network · 200 citations
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanc...
Review article: thiopurines in inflammatory bowel disease
Luc J. J. Derijks, Lennard P. L. Gilissen, P. M. Hooymans et al. · 2006 · Alimentary Pharmacology & Therapeutics · 162 citations
Summary Background In the past 10–20 years, knowledge of both thiopurine pharmacology and ‐pharmacogenetics has been extended dramatically and used to develop new strategies to improve efficacy and...
Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine
Bernd Kaskas, E Louis, U Hindorf et al. · 2002 · Gut · 150 citations
Thiopurine S-methyltransferase (TPMT) deficient patients develop life threatening haematotoxicity (for example, pancytopenia) when treated with a standard dose of azathioprine (AZA) and 6-mercaptop...
Inherited genetic variation in childhood acute lymphoblastic leukemia
Takaya Moriyama, Mary V. Relling, Jun J. Yang · 2015 · Blood · 147 citations
Abstract Although somatically acquired genomic alterations have long been recognized as the hallmarks of acute lymphoblastic leukemia (ALL), the last decade has shown that inherited genetic variati...
Reading Guide
Foundational Papers
Start with Relling et al. (2011) for TPMT guidelines (565 citations), then Lowry et al. (2001) for metabolite assays—these establish core pharmacology cited in all subsequent ALL work.
Recent Advances
Yang et al. (2015) for NUDT15 discovery; Brown et al. (2020) NCCN guidelines; Toksvang et al. (2022) on maintenance therapy integration.
Core Methods
GWAS for variant discovery (Yang 2015); CPIC dosing tiers (0, 30-70%, full dose by genotype, Relling 2011); HPLC for TPMT activity and 6-TGN (Lowry 2001).
How PapersFlow Helps You Research Pharmacogenomics of Thiopurine Therapy
Discover & Search
Research Agent uses searchPapers and exaSearch to find TPMT/NUDT15 papers, then citationGraph reveals Relling et al. (2011) as the hub with 565 citations linking to Yang et al. (2015). findSimilarPapers expands to multi-ethnic studies like Kakuta et al. (2018).
Analyze & Verify
Analysis Agent employs readPaperContent on Yang et al. (2015) GWAS data, runPythonAnalysis for allele frequency stats via pandas, and verifyResponse (CoVe) with GRADE grading to confirm NUDT15's HR=10.3 for intolerance. Statistical verification validates odds ratios across cohorts.
Synthesize & Write
Synthesis Agent detects gaps like missing NUDT15-TPMT combo dosing, flags contradictions in metabolite thresholds. Writing Agent uses latexEditText, latexSyncCitations for guideline tables, latexCompile for reports, and exportMermaid for pharmacogenetic pathway diagrams.
Use Cases
"Run GWAS meta-analysis on TPMT/NUDT15 variants in ALL cohorts"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas meta-analysis on allele frequencies from Yang 2015 + Moriyama 2015) → matplotlib survival curves output.
"Draft LaTeX review of thiopurine dosing guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText (guideline table) → latexSyncCitations (Relling 2011, Brown 2020) → latexCompile → PDF with embedded citations.
"Find GitHub repos analyzing thiopurine pharmacokinetics"
Research Agent → paperExtractUrls (Toksvang 2022) → Code Discovery → paperFindGithubRepo → githubRepoInspect → PK simulation code and Jupyter notebooks.
Automated Workflows
Deep Research workflow scans 50+ thiopurine papers via citationGraph from Relling (2011), producing structured reports with GRADE-scored evidence on TPMT dosing. DeepScan's 7-step chain verifies NUDT15 claims (Yang 2015) with CoVe checkpoints and Python TGN simulations. Theorizer generates hypotheses on dual TPMT/NUDT15 algorithms from maintenance therapy literature (Toksvang 2022).
Frequently Asked Questions
What defines pharmacogenomics of thiopurine therapy in ALL?
It examines TPMT and NUDT15 variants affecting mercaptopurine metabolism, with homozygous TPMT deficiency in 1/300 Caucasians causing 100-fold thioguanine accumulation (Relling et al., 2011).
What are key methods for TPMT/NUDT15 assessment?
Genotyping via PCR for TPMT *2/*3A/*3C and NUDT15 c.415C>T; enzymatic TPMT activity via HPLC (Lowry et al., 2001). Therapeutic drug monitoring measures 6-TGN levels.
What are landmark papers?
Relling et al. (2011, 565 citations) established CPIC TPMT dosing guidelines; Yang et al. (2015, 427 citations) identified NUDT15 via ALL GWAS.
What open problems persist?
Optimal combo TPMT/NUDT15 dosing equations; prospective RCTs in adults; integration with TGN monitoring (Toksvang et al., 2022).
Research Acute Lymphoblastic Leukemia research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pharmacogenomics of Thiopurine Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers